Decisive acceleration of Pfizer and BioNTech stocks on Wall Street in the wake of the final approval of their anti-Covid vaccine by the United States Food and Drug Administration (FDA). The US government body that deals with the regulation of food and pharmaceuticals has approved the Pfizer-BioNTech vaccine as the first vaccine against Covid-19, after it had approved it with the authorization for emergency use (EUA) l ’11 December 2020.
Now the Pfizer-BioNTech vaccine, which will be marketed as Comirnaty, will be used for coronavirus prevention in people aged 16 and over. While it will continue to be available under the Emergency Use Authorization (EUA) for individuals aged 12-15 years and for the administration of a third dose in some immunocompromised individuals.
The news gave wings to the two vaccine producers: the BioNTech stock jumped up by almost 11 percentage points (+ 10.9%), while Pfizer accelerated with + 3.22%.